University Of Notre Dame Du Lac Nektar Therapeutics Transaction History

University Of Notre Dame Du Lac

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$31.0 - $36.3 $1.88 Million - $2.2 Million	-60,589 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$31.58 - $46.35 $1,263 - $1,854	40 Added 0.07%	60,589 $2.04 Million
Q4 2018 Feb 13, 2019	BUY	$30.43 - $56.65 $1.84 Million - $3.43 Million	60,549 New	60,549 $1.99 Million
Q3 2018 Nov 13, 2018	SELL	$46.46 - $68.49 $1.53 Million - $2.26 Million	-32,960 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $4.73 Million - $10.7 Million	-102,352 Reduced 75.64%	32,960 $1.61 Million
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $3.97 Million - $7.49 Million	69,112 Added 104.4%	135,312 $14.4 Million
Q4 2017 Feb 13, 2018	SELL	$23.02 - $60.5 $1.51 Million - $3.97 Million	-65,557 Reduced 49.76%	66,200 $3.95 Million
Q3 2017 Nov 13, 2017	BUY	$17.79 - $24.0 $2.34 Million - $3.16 Million	131,757	131,757 $3.16 Million

146

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $197M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of University Of Notre Dame Du Lac, based on Form 13F filings with the SEC.

Stay updated on University Of Notre Dame Du Lac with notifications on news.